BioCatalystWatch
TENXWorkspace / TENX / OverviewCompany library
TENAX THERAPEUTICS, INC. logo

TENAX THERAPEUTICS, INC.

TENAX THERAPEUTICS, INC. (TENX)

Website

Featured programme · oral formulation of imatinib

Price
Market cap
Next catalyst—
Cash

Chart & Events

Candle interval

Core Clinical

TNX-103 (oral levosimendan)

KATP channel

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

TNX-103 (oral levosimendan)

KATP channel

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Other pipelines

oral formulation of imatinib

BCR-ABL tyrosine kinase

PreINDP1P2P3FilingApproved

History / paused

PDGF receptors × c-KIT × BCR-ABL tyrosine kinase

PreINDP1P2FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

TENX PR & News

PR & News

TENX SEC archive